Elecsys PRO-C3 – BiotechReality – Information Intelligence System for Biopharma

The Elecsys® PRO-C3 test, a novel diagnostic tool created to evaluate the degree of liver fibrosis in individuals exhibiting symptoms of metabolic dysfunction–associated steatotic liver disease (MASLD), was introduced by Roche. The test, which was created in collaboration with Nordic Bioscience, provides physicians with an easy-to-use way to identify individuals who have liver fibrosis of different severity, allowing for prompt intervention and suitable disease treatment. One of the most prevalent causes of chronic liver disease in the developed world, MASLD affects about 30% of the population. A rapidly increasing number of people are living with MASLD, which is mostly caused by diabetes, obesity, and other cardiometabolic risk factors. This condition places a heavy burden on patients and health systems around the world. However, the liver fibrosis linked to MASLD is frequently asymptomatic until the advanced stages and can go undiagnosed for years, even though it is the cause of about one in every 25 deaths worldwide. If left untreated, it can result in serious issues such as liver failure, cirrhosis, and liver cancer. The Elecsys PRO-C3 test addresses an urgent need in the diagnosis, staging and management of liver fibrosis," said Matt Sause, With MASLD affecting a growing number of people worldwide and new treatments emerging, it is critical to detect fibrosis accurately and early. Our innovative solution simplifies the diagnostic process and eases the burden on healthcare services, providing a clear and rapid assessment while reducing the requirement for invasive biopsies. Matt Sause Until recently, there were no medications to treat MASLD; instead, lifestyle changes including diet and exercise, were the mainstay of disease treatment strategies. For the first time, physicians now have a way to improve liver function and delay the advancement of liver fibrosis thanks to the development of new medication therapies. Using Roche's Cobas® analyzers, the Elecsys PRO-C3 test only takes one assay and yields results in only eighteen minutes. Compared to tests that are already accessible, this simplifies the procedure and lowers expenses. When combined with the ADAPT formula4, which takes into account factors like age, diabetes status, platelet count, and PRO-C3 levels, it offers a clear evaluation of the degree of fibrosis, including the ability to differentiate between various severities like cirrhosis (F4), advanced fibrosis (F3), and significant fibrosis (≥F2). This is essential for identifying patients who qualify for novel and cutting-edge medicines as well as for choosing the best course of therapy for them. Source: Hoffmann-La Roche Last Modified:

Tag: Elecsys PRO-C3

Elecsys PRO-C3: Roche’s Precision Test for Liver Fibrosis

Areas Covered

Discover More

GSK Secures Japan Orphan Drug Designation for Risvutatug Rezetecan in Small-Cell Lung Cancer

Pfizer’s Talzenna + Xtandi Delivers Proven rPFS Breakthrough in HRR-Mutated mCSPC

Eli Lilly Declares Powerful 2% A1C Reduction and 17% Weight Loss in Landmark Phase 3 Trial Results of Retatrutide

ICOTYDE FDA Approval: J&J’s First-Line Oral Peptide Breakthrough for Plaque Psoriasis Treatment

Atirmociclib Phase 2 Breakthrough: Pfizer Declares Powerful Results for Metastatic Breast Cancer Treatment

EBGLYSS (lebrikizumab-lbkz) Delivers Remarkable Phase 3 Results for Pediatric Atopic Dermatitis Treatment